AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
State-of-the-art strategies for the diagnosis and management of acromegaly
Authors: Klibanski, A Ho, K Freda, PU Clemmons, DR Barkan, AL Kleinberg, DL Trainer, PJ Swearingen, B Molitch, ME Wass, JAH Thorner, MO Melmed, S Strasburger, CJ Frohman, LA
Citation: A. Klibanski et al., State-of-the-art strategies for the diagnosis and management of acromegaly, ENDOCRINOLO, 11(3), 2001, pp. 223-232
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society (Reprinted from J Clin Endocrinol Metab, vol 85, pg 3990-3993,2000)
Authors: Attie, KM Bengtsson, BA Blethen, SL Blum, W Cameron, F Carel, JC Carlsson, L Chipman, JJ Christiansen, JS Clayton, P Clemmons, DR Cohen, P Drop, S Fujieda, K Ghigo, E Hintz, RL Ho, K Ilondo, MM Jasper, H Jesussek, B Kappelgaard, AM Laron, Z Lippe, BM Malozowski, S Mullis, PE de Muinck-Keizer-Schrama, S Nishi, Y Parks, JS Phelps, C Ranke, M Robinson, I Rosenfeld, RG Rose, S Saenger, P Saggese, G Savage, M Shalet, S Sizonenko, PC Strasburger, C Tachibana, K Tanaka, T Thorner, MO Wikland, KA Zadik, Z
Citation: Km. Attie et al., Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society (Reprinted from J Clin Endocrinol Metab, vol 85, pg 3990-3993,2000), J PED END M, 14(4), 2001, pp. 377-382
Commercial assays available for insulin-like growth factor I and their usein diagnosing growth hormone deficiency
Authors: Clemmons, DR
Citation: Dr. Clemmons, Commercial assays available for insulin-like growth factor I and their usein diagnosing growth hormone deficiency, HORMONE RES, 55, 2001, pp. 73-79
How should insulin-like growth factor I be measured? A consensus statement
Authors: Ranke, MB Feldt-Rasmussen, U Bang, P Baxter, RC Camacho-Hubner, C Clemmons, DR Juul, A Orskove, H Strasburger, CJ
Citation: Mb. Ranke et al., How should insulin-like growth factor I be measured? A consensus statement, HORMONE RES, 55, 2001, pp. 106-109
Relation between serum insulinlike growth factor-1, insulinlike growth factor binding protein-2, and insulinlike growth factor binding protein-3 and nutritional intake in premature infants with bronchopulmonary dysplasia
Authors: Price, WA Lee, E Maynor, A Stiles, AD Clemmons, DR
Citation: Wa. Price et al., Relation between serum insulinlike growth factor-1, insulinlike growth factor binding protein-2, and insulinlike growth factor binding protein-3 and nutritional intake in premature infants with bronchopulmonary dysplasia, J PED GASTR, 32(5), 2001, pp. 542-549
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Authors: van der Lely, AJ Hutson, RK Trainer, PJ Besser, GM Barkan, AL Katznelson, L Klibanski, A Herman-Bonert, V Melmed, S Vance, ML Freda, PU Stewart, PM Friend, KE Clemmons, DR Johannsson, G Stavrou, S Cook, DM Phillips, LS Strasburger, CJ Hacker, S Zib, KA Davis, RJ Scarlett, JA Thorner, M
Citation: Aj. Van Der Lely et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, LANCET, 358(9295), 2001, pp. 1754-1759
Structural analysis of the role of the beta 3 subunit of the alpha V beta 3 integrin in IGF-I signaling
Authors: Maile, LA Badley-Clarke, J Clemmons, DR
Citation: La. Maile et al., Structural analysis of the role of the beta 3 subunit of the alpha V beta 3 integrin in IGF-I signaling, J CELL SCI, 114(7), 2001, pp. 1417-1425
Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis
Authors: Sakai, K Busby, WH Clarke, JB Clemmons, DR
Citation: K. Sakai et al., Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis, J BIOL CHEM, 276(12), 2001, pp. 8740-8745
Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding
Authors: Firth, SM Clemmons, DR Baxter, RC
Citation: Sm. Firth et al., Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding, ENDOCRINOL, 142(5), 2001, pp. 2147-2150
Physiological differences in insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice
Authors: Sakai, K D'Ercole, AJ Murphy, LJ Clemmons, DR
Citation: K. Sakai et al., Physiological differences in insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice, DIABETES, 50(1), 2001, pp. 32-38
Does the GH-IGF axis play a role in cancer pathogenesis?
Authors: Cohen, P Clemmons, DR Rosenfeld, RG
Citation: P. Cohen et al., Does the GH-IGF axis play a role in cancer pathogenesis?, GROWTH H I, 10(6), 2000, pp. 297-305
Growth hormone therapy for hypopituitary adults: Time for re-appraisal
Authors: Barkan, AL Clemmons, DR Molitch, ME Stewart, PM Young, WF
Citation: Al. Barkan et al., Growth hormone therapy for hypopituitary adults: Time for re-appraisal, TRENDS ENDO, 11(6), 2000, pp. 238-245
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
Authors: Trainer, PJ Drake, WM Katznelson, L Freda, PU Herman-Bonert, V van der Lely, AJ Dimaraki, EV Stewart, PM Friend, KE Vance, ML Besser, GM Scarlett, JA Thorner, MO Parkinson, C Klibanski, A Powell, JS Barkan, AL Sheppard, MC Maldonado, M Rose, DR Clemmons, DR Johannson, G Bengtsson, BA Stavrou, S Kleinberg, DL Cook, DM Phillips, LS Bidlingmaier, M Strasburger, CJ Hackett, S Zib, K Bennett, WF Davis, RJ
Citation: Pj. Trainer et al., Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N ENG J MED, 342(16), 2000, pp. 1171-1177
Insulin-like growth factor binding proteins (IGFBPs) in serum and urine and IGFBP-2 protease activity in patients with insulin-dependent diabetes mellitus
Authors: Akinci, A Copeland, KC Garmong, A Clemmons, DR
Citation: A. Akinci et al., Insulin-like growth factor binding proteins (IGFBPs) in serum and urine and IGFBP-2 protease activity in patients with insulin-dependent diabetes mellitus, METABOLISM, 49(5), 2000, pp. 626-633
The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity
Authors: Clemmons, DR Moses, AC McKay, MJ Sommer, A Rosen, DM Ruckle, J
Citation: Dr. Clemmons et al., The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity, J CLIN END, 85(4), 2000, pp. 1518-1524
Testosterone and insulin-like growth factor (IGF) I interact in controlling IGF-binding protein production in androgen-responsive foreskin fibroblasts
Authors: Yoshizawa, A Clemmons, DR
Citation: A. Yoshizawa et Dr. Clemmons, Testosterone and insulin-like growth factor (IGF) I interact in controlling IGF-binding protein production in androgen-responsive foreskin fibroblasts, J CLIN END, 85(4), 2000, pp. 1627-1633
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society
Authors: Israel, E Attie, KM Bengtsson, BA Blethen, SL Blum, W Cameron, F Carel, JC Carlsson, L Chipman, JJ Christiansen, JS Clayton, P Clemmons, DR Cohen, P Drop, S Fujieda, K Ghigo, E Hintz, RL Ho, K Ilondo, MM Jasper, H Jesussek, B Kappelgaard, AM Laron, Z Lippe, BM Malozowski, S Mullis, PE de Munick-Keizer-Schrama, S Nishi, Y Parks, JS Phelps, C Ranke, M Robinson, I Rosenfeld, RG Rose, S Saenger, P Saggese, G Savage, M Shalet, S Sizonenko, PC Strasburger, C Tachibana, K Tanaka, T Thorner, MO Wikland, KA Zadik, Z
Citation: E. Israel et al., Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society, J CLIN END, 85(11), 2000, pp. 3990-3993
The complement component C1s is the protease that accounts for cleavage ofinsulin-like growth factor-binding protein-5 in fibroblast medium
Authors: Busby, WH Nam, TJ Moralez, A Smith, C Jennings, M Clemmons, DR
Citation: Wh. Busby et al., The complement component C1s is the protease that accounts for cleavage ofinsulin-like growth factor-binding protein-5 in fibroblast medium, J BIOL CHEM, 275(48), 2000, pp. 37638-37644
Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and-5 markedly reduce IGF-I binding and alter their biologic actions
Authors: Imai, Y Moralez, A Andag, U Clarke, JB Busby, WH Clemmons, DR
Citation: Y. Imai et al., Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and-5 markedly reduce IGF-I binding and alter their biologic actions, J BIOL CHEM, 275(24), 2000, pp. 18188-18194
Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth
Authors: Nam, TJ Busby, WH Rees, C Clemmons, DR
Citation: Tj. Nam et al., Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth, ENDOCRINOL, 141(3), 2000, pp. 1100-1106
Methods for preparing extracellular matrix and quantifying insulin-like growth factor-binding protein binding to the ECM
Authors: Zheng, B Clemmons, DR
Citation: B. Zheng et Dr. Clemmons, Methods for preparing extracellular matrix and quantifying insulin-like growth factor-binding protein binding to the ECM, METH MOL B, 139, 2000, pp. 221-230
Complex mediation of uterine endometrial epithelial cell growth by insulin-like growth factor-II (IGF-II) and IGF-binding protein-2
Authors: Badinga, L Song, S Simmen, RCM Clarke, JB Clemmons, DR Simmen, FA
Citation: L. Badinga et al., Complex mediation of uterine endometrial epithelial cell growth by insulin-like growth factor-II (IGF-II) and IGF-binding protein-2, J MOL ENDOC, 23(3), 1999, pp. 277-285
Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I
Authors: Imai, Y Clemmons, DR
Citation: Y. Imai et Dr. Clemmons, Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I, ENDOCRINOL, 140(9), 1999, pp. 4228-4235
Synthetic alpha V beta 3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication
Authors: Clemmons, DR Horvitz, G Engleman, W Nichols, T Moralez, A Nickols, GA
Citation: Dr. Clemmons et al., Synthetic alpha V beta 3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication, ENDOCRINOL, 140(10), 1999, pp. 4616-4621
Down-regulation of protein kinase C inhibits insulin-like growth factor I-induced vascular smooth muscle cell proliferation, migration, and gene expression
Authors: Yano, KJ Bauchat, JR Liimatta, MB Clemmons, DR Duan, CM
Citation: Kj. Yano et al., Down-regulation of protein kinase C inhibits insulin-like growth factor I-induced vascular smooth muscle cell proliferation, migration, and gene expression, ENDOCRINOL, 140(10), 1999, pp. 4622-4632
Risultati: 1-25 | 26-27